A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 06 May 2017
At a glance
- Drugs Barasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 21 Apr 2017 Status changed from active, no longer recruiting to completed.
- 09 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018.
- 18 Jul 2016 Planned End Date changed from 1 Jan 2013 to 1 Jun 2017.